ES2525009T3 - Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas - Google Patents

Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas Download PDF

Info

Publication number
ES2525009T3
ES2525009T3 ES09774707.5T ES09774707T ES2525009T3 ES 2525009 T3 ES2525009 T3 ES 2525009T3 ES 09774707 T ES09774707 T ES 09774707T ES 2525009 T3 ES2525009 T3 ES 2525009T3
Authority
ES
Spain
Prior art keywords
glycoproteins
therapeutic uses
lipid mobilization
mobilization properties
properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09774707.5T
Other languages
English (en)
Inventor
Michael J. Tisdale
Steven Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aston University
Original Assignee
Aston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aston University filed Critical Aston University
Application granted granted Critical
Publication of ES2525009T3 publication Critical patent/ES2525009T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Un polipéptido que tiene la secuencia que se muestra en la SEC ID N.º: 1 para uso en la mejora de los síntomas de hiperglucemia administrando al sujeto una dosis terapéuticamente eficaz durante un periodo de 21 días o mayor, en el que existe una mejora continua de los síntomas de hiperglucemia durante el curso del tratamiento.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19

Claims (1)

  1. imagen1
ES09774707.5T 2008-11-07 2009-11-07 Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas Active ES2525009T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11262308P 2008-11-07 2008-11-07
US112623P 2008-11-07
US25302309P 2009-10-19 2009-10-19
US253023P 2009-10-19
PCT/IB2009/007373 WO2010052563A2 (en) 2008-11-07 2009-11-07 Glycoproteins having lipid mobilizing properties and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
ES2525009T3 true ES2525009T3 (es) 2014-12-17

Family

ID=41668450

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09774707.5T Active ES2525009T3 (es) 2008-11-07 2009-11-07 Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas

Country Status (11)

Country Link
US (7) US20100173829A1 (es)
EP (1) EP2355838B1 (es)
JP (6) JP2012508222A (es)
KR (1) KR20110100210A (es)
CN (1) CN102271701A (es)
AU (2) AU2009312539A1 (es)
BR (1) BRPI0921342B1 (es)
CA (1) CA2743026C (es)
ES (1) ES2525009T3 (es)
IL (1) IL212695A0 (es)
WO (1) WO2010052563A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2706913T3 (es) 2010-06-25 2019-04-01 Univ Aston Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
JP6010281B2 (ja) * 2011-03-03 2016-10-19 株式会社カネカ 筋肉増量剤
CN102288601B (zh) * 2011-05-16 2012-12-12 中国药科大学 一种肌球蛋白atp酶活性微量测定方法及其应用
CN102552912A (zh) * 2012-01-30 2012-07-11 林曙光 β3肾上腺素受体阻滞剂的抗肿瘤用途
CA2879250A1 (en) 2012-07-31 2014-02-06 Aston University Targeted oesophageal administration of zn-.alpha.2-glycoproteins (zag), methods and formulations thereof
KR102028245B1 (ko) * 2016-04-06 2019-10-04 연세대학교 산학협력단 피부 건조증 또는 피부 장벽 개선용 조성물 및 항알러지 조성물
CN111201029B (zh) * 2017-09-29 2023-10-24 爱恩斯生物有限公司 Zag来源肽及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308178D0 (en) * 1993-04-21 1993-06-02 Smithkline Beecham Plc Novel compounds
NZ265692A (en) * 1993-06-14 1997-02-24 Pfizer Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions
US5480908A (en) * 1993-12-13 1996-01-02 American Cyanamid Company β3 -adrenergic agents benzodioxole dicarboxylates and their use in pharmaceutical compositions
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
GB9811465D0 (en) 1998-05-29 1998-07-29 Tisdale Michael J Glycoproteins having lipid mobilising properties and therapeutic applications thereof
CN1423637A (zh) * 1999-12-16 2003-06-11 旭化成株式会社 新的取代的三环化合物
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
AUPQ981700A0 (en) * 2000-09-01 2000-09-28 Metabolic Pharmaceuticals Limited Product and method for control of obesity
CA2461491A1 (en) * 2001-10-05 2003-06-19 Ilya Chumakov Methods of screening for antagonists of apm1/gzip
JP2006096666A (ja) * 2002-10-31 2006-04-13 Kaneka Corp 選択的ヒトβ３アドレナリン受容体アゴニスト剤
BR0317323A (pt) * 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicerìdeos microssomal
ATE448229T1 (de) * 2005-01-19 2009-11-15 Merck & Co Inc Bicyclische pyrimidine als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
BRPI0617621A2 (pt) * 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
JP2020122563A (ja) * 2019-01-31 2020-08-13 日本電産株式会社 可撓性外歯歯車および波動歯車装置

Also Published As

Publication number Publication date
AU2009312539A1 (en) 2010-05-14
JP2017002069A (ja) 2017-01-05
US20140243259A1 (en) 2014-08-28
CN102271701A (zh) 2011-12-07
JP2015013872A (ja) 2015-01-22
JP2019116487A (ja) 2019-07-18
JP2012508222A (ja) 2012-04-05
BRPI0921342A2 (pt) 2017-06-06
US20200330554A1 (en) 2020-10-22
WO2010052563A3 (en) 2010-09-16
US20180339019A1 (en) 2018-11-29
CA2743026C (en) 2023-01-03
US20210315969A1 (en) 2021-10-14
CA2743026A1 (en) 2010-05-14
JP2020172540A (ja) 2020-10-22
US20100173829A1 (en) 2010-07-08
WO2010052563A2 (en) 2010-05-14
EP2355838A2 (en) 2011-08-17
IL212695A0 (en) 2011-07-31
EP2355838B1 (en) 2014-09-03
JP2022068320A (ja) 2022-05-09
AU2016204169B2 (en) 2018-02-01
BRPI0921342B1 (pt) 2022-02-01
AU2016204169A1 (en) 2016-07-14
US20240000888A1 (en) 2024-01-04
KR20110100210A (ko) 2011-09-09
US20160220635A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
ES2525009T3 (es) Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
CR9994A (es) Vacuna terapéutica
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
AR081200A1 (es) Formulaciones de insulina de accion prolongada
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
ECSP099178A (es) Método de tratamiento del ictus con un trombolítico
AR077896A1 (es) Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer.
CR20140086A (es) Tratamientos de combinación para hepatitis c
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO6541617A2 (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
AR103118A1 (es) Tratamientos médicos basados en anamorelina
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria